Lamivudine - Shire

Drug Profile

Lamivudine - Shire

Alternative Names: 3TC; 3TC-HBV; BCH 189; BCH 790; Epivir; Epivir-HBV; GR 103665; GR 109714X; Heptodin®; Heptovir; NGPB 21; Victron; Zeffix; Zefix

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Developer Ajinomoto; Aspen Pharmacare; GlaxoSmithKline; GlaxoSmithKline KK
  • Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B; HIV infections; Liver cirrhosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 08 Feb 2018 The US label for lamivudine carries a black box warning related to lactic acidosis and severe hepatomegaly, exacerbations of hepatitis B and different formulations of lamivudine
  • 06 Jun 2012 First generic equivalent available in United Kingdom and Italy for HIV infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top